title: 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.
abstract: A new family of PDE4 inhibitors based on a benzimidazole framework is described. Several of these compounds are orally bioavailable and show efficacy in in vivo models of inflammatory disease.
authors.affiliation: Rhône-Poulenc Rorer, Collegeville, PA 19426, USA.
authors.forename: J
authors.initials: J
authors.lastname: Regan
authors.forename: J
authors.initials: J
authors.lastname: Bruno
authors.forename: D
authors.initials: D
authors.lastname: McGarry
authors.forename: G
authors.initials: G
authors.lastname: Poli
authors.forename: B
authors.initials: B
authors.lastname: Hanney
authors.forename: S
authors.initials: S
authors.lastname: Bower
authors.forename: J
authors.initials: J
authors.lastname: Travis
authors.forename: D
authors.initials: D
authors.lastname: Sweeney
authors.forename: B
authors.initials: B
authors.lastname: Miller
authors.forename: J
authors.initials: J
authors.lastname: Souness
authors.forename: S
authors.initials: S
authors.lastname: Djuric
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D001562:Benzimidazoles / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology*; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D007700:Kinetics; D051379:Mice; D010084:Oxidation-Reduction; D010726:Phosphodiesterase Inhibitors / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D012995:Solubility; D013329:Structure-Activity Relationship
chemical_list: D001562:Benzimidazoles; D010726:Phosphodiesterase Inhibitors; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4